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Abstract
Background: Immunological strategies that achieve the prevention of tumor growth are based on the presumption
that the immune system, if triggered before tumor onset, could be able to defend from speciﬁc cancers. In supporting
this assertion, in the last decade active immunization approaches prevented some virus-related cancers in humans.
An immunopreventive cell vaccine for the non-virus-related human breast cancer has been recently developed. This
vaccine, called Triplex, targets the HER-2-neu oncogene in HER-2/neu transgenic mice and has shown to almost
completely prevent HER-2/neu-driven mammary carcinogenesis when administered with an intensive and life-long
schedule.
Methods: To better understand the preventive eﬃcacy of the Triplex vaccine in reduced schedules we employed a
computational approach. The computer model developed allowed us to test in silico speciﬁc vaccination schedules in
the quest for optimality. Speciﬁcally here we present a parallel genetic algorithm able to suggest optimal vaccination
schedule.
Results & Conclusions: The enormous complexity of combinatorial space to be explored makes this approach the
only possible one. The suggested schedule was then tested in vivo, giving good results. Finally, biologically relevant
outcomes of optimization are presented.
Keywords: Cancer, Optimization, Artiﬁcial intelligence, High performance computing
Background
The role of the immune system in tumor surveillance is
today clearly established, and tumor immunologists are
actively working to devise preventive and therapeutical
vaccines against cancer. Living organisms are natural com-
plex systems and modeling may play a crucial role since
models can also be built with approximate and imperfect
knowledge of the phenomenon, and model parameters
(initial data, entities, relations between entities) can be
adjusted to ﬁt modeling results to experimental measure-
ments [1].
Cancer immunoprevention is a recent development of
tumor immunology that aims at preventing tumor onset
with immunological means, in particular vaccines. The
main challenge issuing from successful experiments in
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genetically-modiﬁedmice is now to translate immunopre-
vention to human situations. In this way, once the vaccine
has been demonstrated to be eﬀective in preventing the
targeted tumor, it is necessary to ﬁnd an optimal vaccina-
tion schedule that minimizes both the administrations of
the vaccine and the eventually present side eﬀects. Obvi-
ously the time and the costs needed for an exhaustive
search are prohibitive [2].
The evaluation of the antitumor eﬃcacy of cancer vac-
cines in mouse models (also here referred to as biological
models) is a required prelude to the clinical use of these
treatments. Testing of some cancer vaccine features, such
as the best conditions for vaccine administration, can be
very diﬃcult or even impossible only through experiments
with biological models simply because a high number of
variables need to be considered at the same time. This
is where computational models can prove handy as they
have shown to be able to reproduce enough biological
complexity to be of use in suggesting new experiments
[3,4]. This characteristic makes computer models suited
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to perform “what-if” analyses to elucidate relationships
between diﬀerent phenomena and to aid in the valida-
tion or rejection of working hypotheses. Indeed, com-
putational models can be used in addition to biological
models.
We developed an agent based model (ABM) of the
eﬀects of a vaccine designed to prevent mammary carci-
noma in transgenic mice [5]. This model faithfully sum-
marizes not only the outcome of vaccination experiments,
but also the dynamics of immune responses elicited by the
vaccine [6-10].
We then used a parallel genetic algorithm to search for
an optimal vaccination schedule. The predicted schedules
were tested in vivo, giving good results [11]. The approach
plays the role of a virtual laboratory performing in a few
days in silico experiments that would take years in vivo.
In order to speed up the search for an optimal vac-
cination schedule, our genetic algorithm is parallelized
using Message Passing Interface (MPI). Furthermore, an
improved master-slaves approach enabled us to exam-
ine high performance measurements in terms of program
execution time and load balancing.
The plan of the paper is the following. Firstly we brieﬂy
introduce the complexity of the biomedical system (inter-
actions of immunity, vaccine and cancer); then we explain
the motivation that leaded to the use of parallel com-
puting. Section “The informatics infrastructure” brieﬂy
describes the core of the vaccine protocols evaluators and
gives a formal deﬁnition of the optimization problem.
Section “Parallelization” brieﬂy introduces the deﬁnition
of parallelization in computer science. Section “Parallel
genetic algorithm” gives the details on the implementation
of the parallel genetic algorithm; section “Results of PGA
over MPI” presents the benchmarks of the approach and
experimentally proves the good performance of the algo-
rithm. Finally in Section “Discussion and Conclusions” we
give our ﬁnal considerations, highlighting the biologically
relevant outcomes of optimization.
For the sake of completeness, we brieﬂy introduce in this
section the main features of the human immune system
and the basic concepts of tumor immunology and cancer
vaccines. Moreover, we focus on the potential of a special
vaccine tested on HER-2/neu transgenic mice.
The immune system
The immune system responds to molecules identiﬁed
as foreign (mainly components of microbes) to pre-
vent infectious diseases, by various mechanisms alto-
gether named immune response [12]. A ﬁrst line of
defense of the immune system is supported by the innate
immunity that includes physical barriers, soluble medi-
ators and specialized killer cells. The innate immune
response remains essentially unaltered by repeated infec-
tions. The adaptive immune system provides a second line
of defense against infections as it recognizes in a spe-
ciﬁc way distinct components called antigens. Lympho-
cytes are the cellular players of this elaborated response
and are able to store information on the acquired anti-
gen recognition, to improve the immune response to
repeated exposures. Finally, the adaptive immunity is
speciﬁc for foreign antigens and tolerant to autologous
(self ) components.
The lymphocytes population includes millions of
clones, each one with a diﬀerent speciﬁc antigen receptor.
This variability among lymphocytes receptors is the rea-
son for lymphocytes ability to recognize a high number of
diﬀerent antigens. Lymphocytes are mainly divided in T
and B cells, and bear antigen receptor molecules on their
cell surface. All of these specialized cells and parts of the
immune system oﬀer the body protection against disease.
This protection is called immunity.
Tumor immunology
Several clinical and preclinical studies highlighted a strong
correlation between immune system weakness and dis-
orderly cell growth. The immune system physiologically
prevents tumor onset, but the incidence of neoplastic dis-
eases proves that cancer immune surveillance is not com-
pletely eﬀective. Reasons for tumor progression could be
related to transient immunodepression, reduced eﬃcacy
of the immune system response with aging and tumor
cell acquisition of the capability to exploit immunological
mechanisms and evade immune surveillance [13-15].
Immune attack made in response to tumors is moved
by both innate and adaptive immunity, including many
molecules and cellular entities that act together and in a
cooperative way in order to limit cancer growth. Brieﬂy,
phagocytes (granulocytes and macrophages), actors of
the innate immunity, directly destroy tumor cells and
produce cell fragments. Antigen presenting cells (APC)
pick up and process these fragments ultimately present-
ing tumor antigens for lymphocyte recognition. Dendritic
cells, which are professional APCs, uptake tumor antigens
in the periphery then migrate to lymph nodes. More-
over, natural killer (NK) cells kill tumor cells with a low
MHC expression and play a key role in the defense against
circulating metastatic cells.
The T helper cell population is the play-maker of the
adaptive immunity team against tumors. Th cells, acti-
vated by antigen recognition on APCs, proliferate and
activate, by cytokine secretion, Tc, phagocytes, NK cells
and B cells. Most solid tumors are protected from anti-
body or complement dependent lysis, consequently in
the antitumor immune response the role of B cells is
(mistakenly) considered marginal. Moreover B cells can
even downregulate T cell responses promoting tumor
growth. Finally also Treg cells can inhibit antitumor
responses [16].
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Cancer vaccines
The idea of developing strategies to support the immune
system against tumors has been producing several
immunological approaches eﬀectively able to limit tumor
growth. These strategies can be passive as monoclonal
antibodies administration, or active as vaccines [17].
The cure of established tumor masses by immunologi-
cal strategies (immunotherapy) has produced poor results
suggesting to address eﬀorts to adequately stimulate
immune system before tumor onset (immunoprevention),
to protect the organism from speciﬁc cancers. Preclinical
studies have shown that prevention is more eﬀective than
cure in the tumor immunology ﬁeld [16].
Cancer vaccines actively enhance a speciﬁc immune
response against target tumor antigens. Tumor antigens
include a huge number of tumor-associated molecules
mostly recognized by the immune system of the host
as self, as they are also expressed by normal cells [18].
Consequently, a successful antitumor immune response
against such self antigens requires to break the immune
tolerance. Among many described tumor antigens, only a
few molecules proved to be good target antigens. Tumor
associated molecules that are essential for tumor growth
and progression could be suitable cancer vaccine targets,
since they cannot be easily downmodulated or negatively
selected in precancerous lesions under the pressure of
a speciﬁc immune attack. Lollini and colleagues have
deﬁned these molecules as oncoantigens [16,19].
Cancer immunoprevention in HER-2/neu transgenic mice
The human epidermal growth factor receptor 2 (referred
to as HER-2 or ErbB2) is amembrane tyrosine kinase over-
expressed in 25-30% of human breast cancers [20]. HER-2
has been widely used as target for immunopreventive
strategies often evaluated against mammary carcinogene-
sis in rat HER-2/neu transgenic mice. A large number of
studies have found treatments able to delay and/or reduce
tumor onset up to a complete protection [19,21].
The Triplex cellular vaccine is one of the most eﬀec-
tive preclinical preventive vaccine [19]. The vaccine is
called Triplex because it has three main components: the
target antigen, HER-2/neu, and two adjuvant stimuli, IL-
12 and allogeneic MHC molecules. IL-12 is needed to
improve antigen presentation and consequently increase
Th cell activation. Allogeneic MHC molecules are rele-
vant to break the tolerance to HER-2/neu self antigen by
stimulatingmultiple T cell clones and causing a broad pro-
duction of immunostimulatory cytokines [17,22]. Mice
were completely protected from mammary tumor onset
by repeated administrations of the Triplex vaccine, start-
ing at an early age (6 weeks of age). Untreated mice had
multiple mammary carcinomas at six months of age while
almost all vaccinated mice were tumor-free at one year of
age doubling the life expectancy of these mice.
Methods & Results
The eﬃcacy of the Triplex vaccine was related to the num-
ber and distribution of administrations along the mouse
life. The Triplex vaccine was administered in mice accord-
ing to chronic protocol based on 4-week vaccination
cycles, starting from 6 week of age for the entire lifetime
of mouse or until one year of age, at least. Mice received
four vaccine administrations over the ﬁrst 2 weeks of each
4-week cycle [22]. Such a high number of vaccinations
actually limits the clinical use of the vaccine because it
reduces patients compliance and increases the risk of side
eﬀects. Only three vaccination cycles were insuﬃcient
[23].
The eﬃcacy of a treatment is strongly dependent on its
dosage and schedule of administration. Many factors have
to be considered in deﬁning a new treatment schedule.
Individual diversity and risk of side eﬀects must be taken
into account. If the former has eﬀects on the minimal
(lower bound) dosage of a treatment, the latter establishes
an upper bound on the maximum allowed dosage to avoid
side eﬀects such as toxicity. To determine the schedule of
a new treatment the common practice is to make use of
the medical consensus, a typical policy where a represen-
tative group of experts in some medical areas commonly
deﬁne the guidelines for the administration of a treatment,
basing their decision on the state-of-the-art knowledge
and past experimental evidence. It is worth to note that in
vivo research focused in ﬁnding better vaccination proto-
cols was discouraging, since it would require many sets of
experiments in vivo, each lasting one year, with prohibitive
costs.
It is now clear that the availability of a computational
methodology that helps biomedical scientists to deﬁne
optimized vaccination schemes would be very useful.
The informatics infrastructure
To tackle the problem of determining if better vaccination
protocols for the Triplex vaccine exist, we developed an
in silico computational model (named SimTriplex) specif-
ically designed to reproduce the eﬀects of Triplex vaccine
against the development of mammary carcinoma in HER-
2/neu transgenic mice [5,24-26]. SimTriplex models all
various classes of immune functional activity, phagocyto-
sis, immune activation, opsonization, infection, cytotoxi-
city and speciﬁc/aspeciﬁc recognition. They are described
using probability functions and translated into compu-
tational rules. An interaction between two entities is a
complex stochastic event which may end with a state
change of one or both entities. Interactions can be spe-
ciﬁc or aspeciﬁc. Speciﬁc interactions need a recogni-
tion phase between the two entities (e.g. B ↔ TAA);
recognition is based on Hamming distance and aﬃnity
function and is eventually enhanced by adjuvants. We
refers to positive interaction when this ﬁrst phase occurs
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successfully. Aspeciﬁc interaction do not have a recogni-
tion phase (e.g. DC ↔ TAA). When two entities, which
may interact, lie in the same lattice site then they inter-
act with a probabilistic law. Both speciﬁc and aspeciﬁc
interactions are stochastically determined using a proba-
bility function, which depends from diﬀerent parameters,
computed via random number generators. Changing the
seed of the random number generator one gets a diﬀer-
ent sequence of probabilistic events. This simulate the
biological diﬀerences between individuals who share the
same events probabilities. In order to model the con-
tinuous carcinogenic process of HER-2/neu transgenic
mice, newborn tumor cells appear at each time step
and are randomly placed on the lattice, whereas existing
tumor cells duplicate. The simulation runs for a num-
ber of steps, typically equivalent to more than 1 year of
real time. If the total number of tumor cells exceeds a
given threshold, which indicates the formation of a pal-
pable tumor mass, the simulation is stopped. Individual
diversity observed in the experimental set-up is simulated
through the use of pseudo-random number generators.
Pseudo-random numbers aﬀect the outcomes of various
probabilistic events at starting of the simulation (e.g. enti-
ties initial position in the lattice) as well as all the events
that happen during the simulation, such as the order and
outcomes of interactions. Each run of the simulator ini-
tialized with a given random number thus represents a
virtual mouse. Experimental variability among mice is
given by the use of diﬀerent seeds for the pseudo-random
number generator.
The optimal vaccination schedule search problem
An optimal schedule maintains its eﬃcacy with a mini-
mum number of vaccine administrations. As in standard
drug administration, the vaccine has to be eﬀective for a
high percentage of patients. In lack of quantitative meth-
ods, this is usually achieved using medical consensus,
i.e. a public statement on a particular aspect of medical
knowledge available at the time it was written, and that
is generally agreed upon as the evidence-based, state-of-
the-art (or state-of-science) knowledge by a representative
group of experts in that area. Our goal is therefore to
have a quantitative approach, using simulators and opti-
mization techniques, that can help biologists in designing
vaccine protocols. It is worth to mention here the fun-
damental deﬁnitions of the optimization problem we will
deal with. Let us consider a time interval [ 0,T], in which
we study the action of the vaccine on a set of virtual mice
S. This can be, for example, the time-length of the in vivo
experiment. We then discretize the given time interval in
N − 1 equally spaced subintervals of width t, i.e. {t1 =
0, t2, . . . , ti, . . . , tN = T}. The time interval t cor-
responds to the time of possible vaccine administrations,
e.g. every 8 hours.
Let x = {x1, x2, . . . , xi, . . . xN } be a binary vector
representing the sequence of vaccine schedule where xi =
0/1 means respectively administration/no administration
of the same quantity of vaccine at time ti. The number
of vaccine administrations is given by n = ∑Ni=1 xi. The
search space D for this problem has therefore cardinality
2N . For T = 400 days, and t = 24 hours the cardi-
nality is 2400 which prevents any chance of an exhaustive
search. Anyway, one wet biologists requirement is that
vaccine administrations can be performed only twice a
week (monday and thursday) and this is already con-
sidered a very intensive vaccination schedule from an
immunological point of view. Luckily, this greatly reduces
the cardinality of the search space D, from 2400 (∼ 10120)
to 2114 (∼ 1034).
To conclude, it is needed an optimization technique
that can deal with this kind of complexity in reasonable
time. In the following we will describe in details what we
developed.
Parallelization
In the informatics ﬁeld, parallelization is the activity that
permits to exploit several computing resources working
at the same time (in parallel), in order to speed up a
computational process.With the increasing of the compu-
tational power, parallelization is gaining more interest and
several kind of solutions are now available, from the mul-
ticore processors mounted in commercial computers to
more complex distributed architecture made up of several
machines.
There are two important aspects to consider when
thinking to use the parallel approach:
• parallelization is not the solution for any type of
application looking for a speed up,
• parallel architectures do not improve the
performance of traditional algorithms written to run
on a single processor.
For what concerns the ﬁrst statement, it is quite simple
verifying whether or not a complex process can beneﬁt
of parallelization: if the tasks that constitute the process
can be performed independently parallelization is possi-
ble. But parallelization is not the merely use of a complex
hardware structure with a high number of CPUs because,
in order to exploit all the potentiality of such architec-
tures, programmers have to write a parallel code that can
be distributed and processed by independent resources.
Moreover, it is worth to highlight that the term resource
can refer both to a hardware and a software entity that
participates to the run of a program. The former resources
are generally the CPU and the diﬀerent type of memory
(like registers, RAM and hard disk) while the latter con-
cern the status of the program in terms of data - which are
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generally stored in the dynamic memories for the runtime
execution (registers and RAM). Therefore, when dealing
with parallelization both the hardware and the software
play an important role for the execution of a code.
In general there are twomain approaches for paralleliza-
tion and the best choice depends on the type of problem
to solve:
1. break up a complex routine into its subroutines and
distribute them to diﬀerent CPUs; in this case CPUs
can access to a shared space of read-only memory in
order to perform computations and have to
synchronize if a subroutine needs the results of
another subroutine;
2. if the process consist of completely independent
routines, parallelization can be performed
distributing these independent routines to diﬀerent
CPUs which synchronize their resources only at the
begin and the end of the process.
While those applications that make use of the ﬁrst
approach could, at limit, turn back into a sequential run
(when any subroutine need the results of the previous
one), iterative simulations represent a good example of
algorithm that can be solved using the second approach;
in this case, ideally, the speed up increases linearly with
the increasing of the number of CPUs.
For what concerns our optimization problem, among
all tried diﬀerent strategies used, the successful one was
represented by the use of genetic algorithm (GA) like
described in [16]. GA [27-29] is a search heuristic meth-
ods used for the resolution of NP-complete problems
characterized by the evaluation of a large number of
possible solutions (population) through a ﬁtness func-
tion. For this reason, GA can be seen as an iterative
algorithm which - at any generation (iteration) - selects
the best set among all the available solutions of the
population, in order to perform the evolutionary pro-
cess and ﬁnd out new and more suitable solution of
the problem.
Parallel genetic algorithm
The GA used in [11] discovered a vaccination schedules
able to avoid solid tumor formation. These results have
encouraged the application and the improvement of the
GA for the seek of the optimum vaccination protocol as, at
the state of the art, the mentioned vaccination schedules
did not prevent the cancer cells to reach an unsafe growth
level and, moreover, did not protect a large percentage of
our population of virtual mice. Having this in mind, we
modiﬁed the GA in order to constrain the research of the
optimum vaccination schedule on a more strict biological
basis that consider the protection of a large class of indi-
viduals and not only a single mouse. For this reason, we
extended the population ofmice and applied the same vac-
cination schedules to 8 randomly chosen mice at the same
time.
The GA has been implemented as in [30] with a simula-
tor that acts as ﬁtness function evaluator for the individ-
uals of the population, representing the possible vaccine
schedules (or therapies). A GA with an attached simulator
is a long and complex computational task and it requires
a prohibitive amount of running time on a single CPU
machine. Since, our GA strategy is based on a population
of 80 individuals to be applied to 8 virtual mice for 150
generations, a run on a single CPUmachine would require
8·80·150·Tﬁt , where Tﬁt is the time needed to evaluate the
ﬁtness function, i.e. to run the simulator. In the previous
equation, the only variable term is Tﬁt , as it depends on
the performance of the hardware. If we suppose that Tﬁt
in a traditional single CPU machine is about 30 seconds,
the previous simulation scenario will take about 32 days.
According to the parallel computing approaches
described in the previous section, the parallel version of
the GA (PGA) can be implemented as shown in Figure 1.
Due to the nature of this algorithm, the MPI technology
was used as it oﬀers a complete set of library for the auto-
matic distribution of the work loads to the pool of the
machines available and the synchronization of the parallel
jobs. When adopting the MPI protocol all the machines
involved receive the same piece of code but, thanks to the
function of the MPI library, they can run selected parts
of it. In particular, MPI functions permit to automatically
deﬁne a machine as the master which is in charge to
execute the sequential parts of the code and conﬁgure all
the simulation environment(see the operations sketched
in the Set Simulation Environment); moreover the MPI
functions will detect all the other resources allowing the
master machine to synchronize them with the simulation
data to use for the parallel jobs.
For what concerns our PGA, as it is shown in Figure 1,
the algorithm consists of the following sequential steps
• Set Simulation Environment and Set and Share the
Population, for the conﬁguration and the
synchronization of the machines and
• a pure parallel segment of code inside the Loop on
the n. generations where the discovered available
resources are automatically conﬁgured to run
assigned pieces of simulation (execute simulator) in
parallel.
At ﬁrst, as a traditional GA, the master machine
will conﬁgure the ﬁrst generation of individuals that
are passed to the other machines through the MPI
function MPI Bcast(·). After that, the resources syn-
chronize MPI Barrier(·) and start their scheduled jobs
in parallel. Once all the machines have ﬁnished and
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their computations synchronized, the Master collects
and organizes these results in order to compute the
ﬁtness function and start the process of evolution
for the enhancement of the population. The pro-
cess will continue until the number of generations
over.
Once parallelism is incorporated into the GA, signif-
icant amounts of time can be saved. These results are
signiﬁcant also from a biological point, both in terms of
time, mice and costs perspectives; they can be appreci-
ated looking Table 1: the virtual laboratory implemented
permitted to enlarge the number of therapies from 16
to 128, showing that it was possible to test a large
amount of vaccine schedules within a reasonable period
of time.
Results of PGA overMPI
Figure 2 depicts the results of the simulations of Table 1,
providing other interesting insights; in fact, it shows the
linear decreasing of the Tg (the time needed to perform
one genetic algorithm generation), due to the usage of
an increasing number of CPUs. These set of data were
collected ﬁxing the number of individuals of the pop-
ulation (from 16 to 128) scaling the number of CPUs
from 4 to 256. For instance, let us to consider the top
frame on the left of Figure 2, corresponding to the sim-
ulations of the PGA with 16 individuals; according to
the results of Table 1, the time to perform one genera-
tion using 4 CPUs is about 7.66 minutes and doubling
the number of CPUs to 8 the time needed decreases to
4.95 minutes. Again, if we double to 16 the number of
CPUs the time of Tg keeps lowering to 3.5 minutes, con-
ﬁrming that it follows a negative slope typical of a linear
function.
The same trend appears also looking at the other graph-
ics and help to observe that the slopes of the curves
become tinier to a threshold which indicates the lower
bound for any Tg (from 16 to 128 individuals), no matter
the number of CPUs exploited. This result does not have
to surprise and suggests some important considerations;
in fact, on one side they conﬁrm the eﬀectiveness of the
Figure 1 PGA ﬂowchart.
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Table 1 Running time over diﬀerent number of processors
and therapies






















The number of virtual mice are always set to 8
approach, showing the way how acting on the number of
CPUs it is possible to scale linearly the time of computa-
tion but, above all, they reveal what is the bottleneck of the
algorithm beyond which the increasing of CPUs do not
improve the performance of the computation. This limit
is related to the contribute of
1. the waiting time due to the operations of
synchronization among the CPU slaves and
2. the time of computation performed by the master
CPU, at the beginning of a new generation, for the
construction of the new individuals of the PGA
population (the vaccine schedules).
As it is highlighted in Table 1 this limit tends to increase
from about 3.5 minutes for 16 individuals (using up to
16 CPUs) to 5 minutes for 128 individuals (using up to
128 CPUs). The reason why it cannot be lowered is that
the operations of evolutions for the ith generation (i.e., the
updating of new individuals at the beginning of a genera-
tion, typical of a genetic algorithm) cannot be parallelized
and have to be performed always by the master CPU, once
it has collected all the resulting data of the (i−1)th genera-
tion coming from the slave CPUs; this result is highlighted
in Figure 3, showing how the time for the master CPU to
process a new genetic population tends to increase with
the number of individuals.
Discussion and Conclusions
Optimization theory has a long tradition and the tech-
niques are numerous. Most of the practical problems
in physics, engineering and applied mathematics can be
formulated as optimization problems. From this perspec-
tive the search for an optimized therapeutic protocol for
the administration of a vaccine is no exception. In this
article we have tried to show how this search for the
best vaccine administration in terms of dosage and tim-
ings can be formulated as an optimization problem and
then, how it can be solved using well-known well known
artiﬁcial intelligence methodologies over supercomputing
infrastructures.
The quality of the optimized protocol is strictly related
to the goodness of the model. In particular the direct or
indirect eﬀects of the therapeutic agents on the malig-
nancy need to be carefully taken into account since the
optimization algorithms rely on a scoring method that
price the solutions on the basis of their eﬀects. Having
this said, it appears clear that the more sophisticated and
detailed the model is, the higher the chances to obtain an
eﬃcacious eﬀect of the optimized therapy once it goes to
the test bed.
We started from a real question: is it possible to
reduce the number of Triplex vaccine administrations
and maintain a high preventive eﬃcacy? This is a typi-
cal clinical question that. The work we have described in
this article showed that modeling is a concrete tool for
study of cancer immunopreventive strategies and there-
fore can help in answering that question in the biomedical
world.
From the biomedical point of view, the main outcomes
of the suggested protocol, after its long term in vivo valida-
tion, can be summarized as following. As predicted in sil-
ico, many vaccinations of the Chronic protocol are redun-
dant and can be avoided. A rapid priming of young mice is
required for long-term protection from tumor onset, and
the accuracy of mathematical modeling of early immune
responses is critical. Finally, the model should take into
account the ageing of the immune system. As presented in
[11], the protocol of vaccination should be revised in the
elderly hosts.
In this paper, we presented a parallel framework to exe-
cute a genetic algorithm that uses a simulator as a ﬁtness
evaluator. It suggested near optimal vaccination sched-
ule that was then tried in vivo. The run of this kind of
genetic algorithm would have required about 32 days for
a single run. We then implemented the genetic algorithm
over MPI technology. The main problem to be deal with
was the linear scaling of the implementation. We used
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Figure 2 Results of the simulations of Table 1. It shows the linear decreasing of the Tg (time expressed in minutes) due to the usage of an
increasing number of CPUs. These set of data were collected ﬁxing the number of individuals of the population (from 16 to 128) scaling the number
of CPUs from 4 to 256.
a master-slave approach that allowed us to have a good
linearity scaling, optimizing the use of the available CPUs.
Parallel computing was successfully applied in drug
optimization, leading to the development of a real virtual
lab to analyze and optimize vaccine protocol administra-
tions.
It is worth to mention that, in the view of real possi-
ble applications in biomedical informatics, for example in
hospitals, it is unlikely that clinics or hospitals own HPC
Figure 3 Time (in minutes) for the master CPU to process a new
genetic population; it tends to increase with the number of
individuals.
infrastructure dedicated to a virtual lab. However nowa-
days computer science technology advances created HPC
systems (think about multi-cores computers) that can ﬁt
in a doctor’s room.
To conclude, we can not forget what is the other side of
the coin.Models are simpliﬁcations of reality and as a such
can leave apart important aspects of the phenomenon
under study. A goodmodel needs to be based on clinical or
preclinical data and its improvement needs to make use of
available clinical and preclinical testing of predicted data.
Only through a carefully checked adherence with reality
we can hope that our model produces useful meaningful
biological knowledge. Perhaps not perfectly accurate but
at least instructive.
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